Back to News
Market Impact: 0.32

Jefferies raises Voyager Technologies stock price target on Starlab opportunity

Analyst EstimatesAnalyst InsightsCompany FundamentalsCorporate Guidance & OutlookInfrastructure & DefenseTechnology & InnovationIPOs & SPACsInvestor Sentiment & Positioning
Jefferies raises Voyager Technologies stock price target on Starlab opportunity

Jefferies raised Voyager Technologies' price target to $60 from $40 while keeping a Buy rating, implying 32% upside from the current $45.57 share price. The firm highlighted a $5 billion pipeline and valued Starlab at $18 per share, but the key Starlab RFP is now expected to slip by 3-6 months. Voyager also won a $16.5 million DARPA contract, and Wedbush separately lifted its target to $60 on confidence in revenue growth through 2027.

Analysis

The market is starting to price Voyager as a platform asset rather than a single-program story, which is why multiple brokers can lift targets even as the core catalyst slips in time. The key second-order effect is that a delayed Starlab decision does not kill the thesis; it extends the window for backlog conversion to prove out, while also keeping scarcity value elevated in a sector getting bid on the SpaceX IPO spillover. That tends to favor names with visible defense-funded work and near-term contract cadence over pure concept names.

The real engine here is not the delayed space-station decision, but the mix shift toward dual-use defense payloads and propulsion-adjacent IP, which reduces dependence on one binary space commercialization event. A $275M backlog is meaningful only if conversion is front-loaded into 2026, so the stock’s next leg likely depends on whether management can keep the revenue bridge intact through incremental awards rather than headline RFP wins. If that cadence stalls for even one quarter, the market will re-rate the story from "platform premium" back to "long-duration optionality."

Consensus is underestimating how fragile the current multiple is to execution slippage after a 130% six-month run. The stock can remain overbought for months, but the asymmetric risk is that any delay in Starlab plus no fresh large defense award would force investors to pay up for revenue far beyond 2026, which is a dangerous setup if rates stay restrictive. The contrarian view is that the best risk-adjusted expression may be to own the business only through catalysts with hard near-term cash conversion, and fade the multiple expansion once the next contract print is behind it.